EUVIMEDEUVIMED entdecken
Multizentrische Studie

One-Year Patient Survival After COVID-19-Associated Rhino-Orbital-Cerebral Mucormycosis: A Multicenter Study

Bahram Eshraghi, Behzad Khademi, Mohsen Bahmani Kashkouli, Gholamreza Khataminia, Mohammad Yaser Kiarudi, Reza Nabie, Mahdi Abounoori, Samira Chaibakhsh, Hossein Ghahvehchian, Fereshte Rastegarnasab, Mohammadmehdi Parandin, Zahra Zia und 16 weitere

Mycopathologia · 2025-08 · 190 (4)

DOI: 10.1007/s11046-025-00966-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Mycopathologia, online erschienen am 06.07.2025. Verfasst von Bahram Eshraghi und 27 weiteren Autor:innen. Beteiligte Einrichtung: Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran. Hauptthemen laut MEDLINE: Mucormycosis, COVID-19, Orbital Diseases, Brain Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Since December 2019, a serious health crisis caused by severe acute respiratory syndrome-Coronavirus-2 affected all aspects of human lives. The available data about COVID-19-associated Rhino-Orbital-Cerebral Mucormycosis (CA-ROCM) survival issues are based on studies on small populations with limited follow-up durations. Therefore, this multicenter cohort of a large population with CA-ROCM is aiming to report the one-year survival rate and investigate the potential responsible risk factors affecting the mortality. MATERIALS AND METHODS: This prospective, longitudinal, multicenter study included CA-ROCM patients from eight tertiary ophthalmology centers across Iran. Demographic, clinical, and therapeutic data were collected and patients were followed for a year. Survival analysis was performed using Cox proportional hazards models to identify mortality-associated risk factors. The research protocol is also available on ClinicalTrials.gov (NCT05097664). RESULTS: Among the 246 patients, 183 (74.4%) survived within a year and 63 (25.6%) died. Significant mortality risk factors included need for orbital exenteration (HR = 3.01 vs. other treatments, p = 0.019), advanced disease stage (HR = 2.43 stage IV vs. II, p = 0.02), age (HR = 1.05, p < 0.001), and diabetes duration (HR = 1.05, p = 0.002). Paradoxically, steroid administration for COVID management was associated with improved survival (HR = 2.72 for no steroids, p = 0.018). DISCUSSION: COVID-19-associated Rhino-Orbital-Cerebral Mucormycosis carries a substantial one-year survival rate of 74.4% in Iran. Age, diabetes, advanced disease stage, and need for orbital exenteration are the probable fatal risk factors. Interestingly, administration of steroids for COVID management was associated with a better survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MucormycosisCOVID-19Orbital DiseasesBrain DiseasesHumansFemaleMaleMiddle AgedProspective StudiesIranAdultRisk FactorsAgedLongitudinal StudiesSARS-CoV-2Survival Analysis

Stichwörter der Autor:innen

COVID-19COVID-19-associated mucormycosisDiabetesMortalityMucormycosis

Autor:innen und Institutionen

  • Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Department of Ophthalmology, University of Texas Health at San Antonio, San Antonio, TX, USA.
  • Poostchi Ophthalmology Research Center, Department of Ophthalmology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Ophthalmology and Visual Sciences, University of Louisville School of Medicine, Louisville, KY, USA.
  • Infectious Ophthalmologic Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  • Department of Ophthalmology of Ahvaz, Jundishapur University of Medical Sciences, Ahvaz, Iran.

Zitieren

APA

Eshraghi, B., Khademi, B., Bahmani Kashkouli, M., Khataminia, G., Kiarudi, M. Y., Nabie, R., Abounoori, M., Chaibakhsh, S., Ghahvehchian, H., Rastegarnasab, F., Parandin, M., Zia, Z., Karamirad, S., Jafarpour, S., Fakoor, M., Varshochi, M., Mirmohammadkhani, M., Ramezani-Majd, A., Janipour, M., …, & Pourazizi, M. (2025). One-Year Patient Survival After COVID-19-Associated Rhino-Orbital-Cerebral Mucormycosis: A Multicenter Study. Mycopathologia, 190(4). https://doi.org/10.1007/s11046-025-00966-2

Vancouver

Eshraghi B, Khademi B, Bahmani Kashkouli M, Khataminia G, Kiarudi MY, Nabie R, et al. One-Year Patient Survival After COVID-19-Associated Rhino-Orbital-Cerebral Mucormycosis: A Multicenter Study. Mycopathologia. 2025;190(4). doi:10.1007/s11046-025-00966-2

BibTeX
@article{Eshraghi2025,
  author = {Eshraghi, Bahram and Khademi, Behzad and Bahmani Kashkouli, Mohsen and Khataminia, Gholamreza and Kiarudi, Mohammad Yaser and Nabie, Reza and Abounoori, Mahdi and Chaibakhsh, Samira and Ghahvehchian, Hossein and Rastegarnasab, Fereshte and Parandin, Mohammadmehdi and Zia, Zahra and Karamirad, Soroush and Jafarpour, Soheyla and Fakoor, Mostafa and Varshochi, Mojtaba and Mirmohammadkhani, Majid and Ramezani-Majd, Alireza and Janipour, Masoud and Mahdian Rad, Atefe and Shekarchian, Farid and Manouchehri, Vahideh and Sajjadi, S Mohammad Javad and Etezad Razavi, Mohammad and Khosropour, Hajar and Forouhari, Ali and Ebrahimi, Fatemeh and Pourazizi, Mohsen},
  title = {One-Year Patient Survival After COVID-19-Associated Rhino-Orbital-Cerebral Mucormycosis: A Multicenter Study},
  journal = {Mycopathologia},
  year = {2025},
  volume = {190},
  number = {4},
  doi = {10.1007/s11046-025-00966-2}
}
Kostenlos starten →